CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Cephalon, Inc. v. Sagent Pharmaceuticals Inc.

1:14-cv-01116

Overview

Case Number 1:14-cv-01116
Filing Date 2014-09-02
Status Terminated
Termination Date 2016-08-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sagent Agila LLC Operating Company

Represented By

1 Attorneys Listed

Shanti Mulpuru Katona

Polsinelli PC

Tel: +1 (302) 252-0924

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Sagent Pharmaceuticals Inc. Operating Company

Represented By

4 Attorneys Listed

Richard Montgomery Donaldson

Polsinelli PC

Tel: +1 (302) 252-0920

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Tedd W. Van Buskirk

Email: tvanbuskirk@daignaultiyer.com

Shanti Mulpuru Katona

Polsinelli PC

Tel: +1 (302) 252-0924

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Ronald M. Daignault

Email: rdaignault@daignaultiyer.com

Plaintiff

Cephalon, Inc. Operating Company

Represented By

4 Attorneys Listed

Stephanie E. O'Byrne

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6067

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

David M. Fry

JPMorgan Chase & Co.

Tel: +1 (302) 455-3374

JPMorgan Chase & Co., 4041 Ogletown Stanton Road

John W. Shaw

Shaw Keller LLP

Tel: +1 (302) 298-0701

I.M. Pei Building, 1105 North Market Street

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 3 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (3 found):
PTAB: 3
USPTO PTAB Trial 2015-10-28
IPR2016-00098

Fresenius Kabi USA, LLC v. Cephalon, Inc.

U.S. Continuation Sibling (8791270)
Status: Terminated-Settled
USPTO PTAB Trial 2015-10-09
IPR2016-00026

AGILA SPECIALTIES INC. et al. v. Cephalon, Inc.

U.S. Continuation Sibling (8791270)
Status: Institution Denied
USPTO PTAB Trial 2014-12-24
IPR2015-00503

AGILA SPECIALTIES INC. v. Cephalon, Inc.

U.S. Continuation Sibling (8436190)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8445524
Solid forms of bendamustine hydrochloride
Filed: 2011-11-22
Issued: 2013-05-21
Active (5.0 yrs remaining)
Expires: 2031-11-22
US8436190
Bendamustine pharmaceutical compositions
Filed: 2006-01-12
Issued: 2013-05-07
Active (3.9 yrs remaining) +1748d PTA
Expires: 2030-10-26
US8609863
Bendamustine pharmaceutical compositions
Filed: 2012-12-19
Issued: 2013-12-17
Active (6.1 yrs remaining)
Expires: 2032-12-19
US8791270
Bendamustine pharmaceutical compositions
Filed: 2013-08-19
Issued: 2014-07-29
Active (6.7 yrs remaining)
Expires: 2033-08-19

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

1

Granted

0

Denied

0

Pending / Review

0

Motions by Category

Claim Construction / Markman Filing 2 Motion to Dismiss 1

Key Dispositive Motions & Rulings

Motion to Dismiss Pending
Remark : Cases are consolidated for all purposes. All future filings shall be made only in lead CA 13-2046 GMS, including documents relating to the pending Moti...
Entry #β€” • 2014-11-24
Claim Construction / Markman Filing Pending
SO ORDERED - Proposed Scheduling Order filed by Cephalon, Inc. Setting Scheduling Order Deadlines: Cases are consolidated for all purposes. All future filings s...
Entry #β€” • 2014-11-24
Claim Construction / Markman Filing Pending
Minute Entry for proceedings held before Judge Gregory M. Sleet - Scheduling Conference held on 10/30/2014. These cases are consolidated for all purposes. Couns...
Entry #β€” • 2014-10-31

Docket Entries

(36 total)
Pleading / Complaint

COMPLAINT filed against Sagent Agila LLC, Sagent Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1580263.) - filed by Cephalon, Inc.. (Attachments: # 1 Exhibit A Part 1 of 3, # 2 Exhibit A Part 2 of 3, # 3 Exhibit A Part 3 of 3, # 4 Civil Cover Sheet)(mas) (Entered: 09/03/2014)

Entry #1 • 2014-09-02
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mas) (Entered: 09/03/2014)

Entry #2 • 2014-09-02
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/25/2014. Date of Expiration of Patent: 03/26/2029.Thirty Month Stay Deadline: 1/28/2017. (mas) (Entered: 09/03/2014)

Entry #3 • 2014-09-02
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,445,524 B2; US 8,436,190 B2; US 8,609,863 B2; US 8,791,270 B2;. (mas) (Entered: 09/03/2014)

Entry #4 • 2014-09-02
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceutical Industries Ltd for Cephalon, Inc. filed by Cephalon, Inc.. (mas) (Entered: 09/03/2014)

Entry #5 • 2014-09-02
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc